Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant and Postoperative Sunitinib in Metastatic Renal Cell Carcinoma
2005-004502-82Phase 2Terminated
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in metastatic renal cell carcinoma (mRCC), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Objective response rate. Started Aug 2009; status: terminated.
02
Drugs
sunitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2005-004502-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004502-82.